TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 33934709

Group type: EXPERIMENTAL
Intervention: Decision aid group (web-based decision aid created by Healthwise)
Number of subjects: 300

Group type: COMPARATOR
Intervention: Control group (information about driving without evidence-based elements)
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Decision aid group
Number of subjects: 300

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 300
Study: 33934715

Group type: EXPERIMENTAL
Intervention: Essen-ICH-score
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: max-ICH score
Number of subjects: 0

Group type: COMPARATOR
Intervention: Various prediction scores
Number of subjects: 0
Study: 33935163

Group type: EXPERIMENTAL
Intervention: Community-acquired pneumonia-macrophage activation-like syndrome (n = 15; 9.8%)
Number of subjects: 153

Group type: COMPARATOR
Intervention: Community-acquired pneumonia-control (n = 138; 90.2%)
Number of subjects: 153

Group type: EXPERIMENTAL
Intervention: Community-acquired pneumonia-macrophage activation-like syndrome (n = 15)
Number of subjects: 153

Group type: COMPARATOR
Intervention: Community-acquired pneumonia-control (n = 138)
Number of subjects: 153

Group type: EXPERIMENTAL
Intervention: Subgroup analysis excluding patients with hematologic malignancies (n = 141)
Number of subjects: 153
Study: 33935214

Group type: EXPERIMENTAL
Intervention: Psychoneurological symptoms in Study 1
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Psychoneurological symptoms in Study 2
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Psychoneurological symptoms mediating stressors and maternal functions in Study 2
Number of subjects: 0
Study: 33935282

Group type: EXPERIMENTAL
Intervention: 12-week supervised combined aerobic resistance-exercise program
Number of subjects: 1983

Group type: COMPARATOR
Intervention: Physical activity level (less active vs more active)
Number of subjects: 1983

Group type: COMPARATOR
Intervention: Exercise training
Number of subjects: 1983
Study: 33935738

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 33935773

Group type: EXPERIMENTAL
Intervention: Tramadol
Number of subjects: 0
Study: 33935825

Group type: EXPERIMENTAL
Intervention: Modular Psychotherapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 33935935

Group type: EXPERIMENTAL
Intervention: Early Orthostatic Exercise by Head-Up Tilt With Stepping
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard Care
Number of subjects: 0
Study: 33935966

Group type: EXPERIMENTAL
Intervention: Inhibin B
Number of subjects: 2524

Group type: COMPARATOR
Intervention: FSH
Number of subjects: 2524
Study: 33936110

Group type: EXPERIMENTAL
Intervention: Elevated TNFα (median (IQR): 8.2 (6.4-9.8) pg/ml)
Number of subjects: 783

Group type: EXPERIMENTAL
Intervention: Elevated IL-1β (0.21 (0.1-0.4) pg/ml)
Number of subjects: 783
Study: 33936809

Group type: EXPERIMENTAL
Intervention: Fovea-sparing ILM peeling technique
Number of subjects: 5
Study: 33936953

Group type: EXPERIMENTAL
Intervention: NO-FEAR Airlines with navigable images
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: NO-FEAR Airlines with still images
Number of subjects: 60

Group type: COMPARATOR
Intervention: Waiting list control group
Number of subjects: 60
Study: 33937527

Group type: EXPERIMENTAL
Intervention: Gonadotropin-Releasing Hormone Agonists
Number of subjects: 0
Study: 33937603

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 33937611

Group type: EXPERIMENTAL
Intervention: Self-efficacy intervention for coping with breast cancer treatment
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 33937624

Group type: EXPERIMENTAL
Intervention: Presence of somatic mutations of estrogen receptor alpha
Number of subjects: 3217
Study: 33937906

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 33937953

Group type: EXPERIMENTAL
Intervention: Lorlatinib 100 mg co-administered with modafinil 400 mg/day
Number of subjects: 16

Group type: COMPARATOR
Intervention: Lorlatinib 100 mg alone
Number of subjects: 16
Study: 33937954

Group type: EXPERIMENTAL
Intervention: Lorlatinib (10-200 mg orally once daily and twice-daily doses of 35, 75, and 100 mg in continuous 21-day cycles for phase I; 100 mg once daily in continuous 21-day cycles for phase II)
Number of subjects: 329

Group type: EXPERIMENTAL
Intervention: Lorlatinib
Number of subjects: 329
Study: 33938407

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 33938716

Group type: EXPERIMENTAL
Intervention: Host response bacterial/viral test
Number of subjects: 623

Group type: COMPARATOR
Intervention: Procalcitonin
Number of subjects: 623
Study: 33938805

Group type: EXPERIMENTAL
Intervention: Nam Nalavazhvu intervention (norm-centric behavior change intervention)
Number of subjects: 76

Group type: COMPARATOR
Intervention: Control group (counterfactuals)
Number of subjects: 76
Study: 33939006

Group type: EXPERIMENTAL
Intervention: Narrow diameter implants in T2DM patients (HbA1C > 6.5%)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Narrow diameter implants in normo-glycemic patients (HbA1C < 6.0%)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Narrow diameter implants in both groups
Number of subjects: 32
Study: 33939067

Group type: EXPERIMENTAL
Intervention: DSP-7888 administered intradermally (ID) at doses of 3.5 mg, 10.5 mg, and 17.5 mg.
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: DSP-7888 administered subcutaneously (SC) at doses of 3.5 mg and 10.5 mg.
Number of subjects: 24
Study: 33939068

Group type: EXPERIMENTAL
Intervention: Savolitinib monotherapy 400 mg once daily (qd)
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Savolitinib monotherapy 600 mg qd
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Savolitinib 400 mg qd + Osimertinib 80 mg
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Savolitinib 300 mg qd + Osimertinib 80 mg
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Savolitinib 600 mg qd + Osimertinib 80 mg
Number of subjects: 29
Study: 33939124

Group type: EXPERIMENTAL
Intervention: HPV infection
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: High-risk HPV infections
Number of subjects: 0
Study: 33939158

Group type: EXPERIMENTAL
Intervention: tiotropium/olodaterol Respimat
Number of subjects: 0
Study: 33939529

Group type: EXPERIMENTAL
Intervention: Age-adjusted D-Dimer cutoff
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard D-Dimer cutoff
Number of subjects: 0
Study: 33939604

Group type: EXPERIMENTAL
Intervention: Coronary intravascular lithotripsy (IVL)
Number of subjects: 628
Study: 33940581

Group type: EXPERIMENTAL
Intervention: Telotristat ethyl (250 or 500 mg thrice daily)
Number of subjects: 124

Group type: EXPERIMENTAL
Intervention: Telotristat ethyl
Number of subjects: 124
Study: 33940642

Group type: COMPARATOR
Intervention: Cross-sectional fundal height measurement ≤ -3 cm at visit 3 (mean: 32.0 ± 1.6 weeks)
Number of subjects: 1939

Group type: EXPERIMENTAL
Intervention: Addition of longitudinal fundal height
Number of subjects: 1939
Study: 33941089

Group type: EXPERIMENTAL
Intervention: Stakeholder-engaged process for refining the design of a clinical trial in home hospice
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Stakeholder engagement process
Number of subjects: 9
Study: 33941111

Group type: EXPERIMENTAL
Intervention: Kilovoltage Intrafraction Monitoring (KIM) guidance
Number of subjects: 46

Group type: COMPARATOR
Intervention: Stereotactic Ablative Body Radiotherapy (SABR)
Number of subjects: 46
Study: 33941281

Group type: EXPERIMENTAL
Intervention: IL-9
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: IL-9-producing CD4(+) T cells
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: IL-9 and D-lactate levels
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: IL-9 blockade
Number of subjects: 0

Group type: COMPARATOR
Intervention: Serum IL-9-producing CD4(+) T cell percentages, IL-9, and D-lactate levels
Number of subjects: 0
Study: 33941784

Group type: EXPERIMENTAL
Intervention: Rucaparib (PARP inhibitor)
Number of subjects: 0
Study: 33941878

Group type: EXPERIMENTAL
Intervention: WNT974 (10 mg once-daily)
Number of subjects: 94
Study: 33942031

Group type: EXPERIMENTAL
Intervention: SARS-CoV-2 serology testing
Number of subjects: 3028

Group type: EXPERIMENTAL
Intervention: Symptomatic COVID-19
Number of subjects: 3028

Group type: EXPERIMENTAL
Intervention: Higher concentrations of C-reactive protein
Number of subjects: 3028

Group type: EXPERIMENTAL
Intervention: Higher numbers of recent disease flares
Number of subjects: 3028

Group type: EXPERIMENTAL
Intervention: Use of biological therapy
Number of subjects: 3028

Group type: EXPERIMENTAL
Intervention: Recent disease flares
Number of subjects: 3028

Group type: EXPERIMENTAL
Intervention: Treatment changes due to the pandemic
Number of subjects: 3028
Study: 33942128

Group type: EXPERIMENTAL
Intervention: Ponatinib treatment
Number of subjects: 50
Study: 33942298

Group type: EXPERIMENTAL
Intervention: Novel MYC-non-IG fusion treatment
Number of subjects: 0
Study: 33942348

Group type: EXPERIMENTAL
Intervention: Rituximab-bendamustine for a median of 6 cycles
Number of subjects: 175
Study: 33942358

Group type: EXPERIMENTAL
Intervention: Clinical decision rule informed by multivariate analysis
Number of subjects: 1288

Group type: EXPERIMENTAL
Intervention: BI-RADS descriptors associated with malignancy
Number of subjects: 1288

Group type: EXPERIMENTAL
Intervention: Histopathologic evaluation
Number of subjects: 1288

Group type: EXPERIMENTAL
Intervention: Inter-reader reliability of BI-RADS descriptors
Number of subjects: 1288
Study: 33942491

Group type: EXPERIMENTAL
Intervention: Alemtuzumab induction followed by belatacept/rapamycin-based immunosuppression over 36 months
Number of subjects: 0

Group type: COMPARATOR
Intervention: Alemtuzumab induction followed by belatacept/rapamycin-based immunosuppression
Number of subjects: 0
Study: 33942621

Group type: EXPERIMENTAL
Intervention: Standardized diluted diesel exhaust (300 µg/m³)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Filtered air with an exposure mask
Number of subjects: 16

Group type: COMPARATOR
Intervention: Filtered air
Number of subjects: 16
Study: 33942675

Group type: EXPERIMENTAL
Intervention: Fondaparinux
Number of subjects: 120
Study: 33942745

Group type: EXPERIMENTAL
Intervention: Cricothyroid method for lignocaine administration
Number of subjects: 365

Group type: COMPARATOR
Intervention: Spray-as-you-go method for lignocaine administration
Number of subjects: 365
Study: 33942954

Group type: EXPERIMENTAL
Intervention: Cemiplimab plus radiation therapy, cyclophosphamide, and granulocyte macrophage colony-stimulating factor (GM-CSF)
Number of subjects: 15
Study: 33943025

Group type: EXPERIMENTAL
Intervention: T2DM group (93 individuals with obesity and T2DM)
Number of subjects: 174

Group type: COMPARATOR
Intervention: OB group (66 individuals with obesity without T2DM)
Number of subjects: 174

Group type: COMPARATOR
Intervention: NGT group (15 individuals with normal BMI and normal glucose tolerance)
Number of subjects: 174

Group type: EXPERIMENTAL
Intervention: Adipocyte hypertrophy
Number of subjects: 174
Study: 33944790

Group type: EXPERIMENTAL
Intervention: SensiumVitals monitoring system (preimplementation phase) alongside usual care
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: SensiumVitals monitoring system with digital alerts (postimplementation phase)
Number of subjects: 0
Study: 33944807

Group type: EXPERIMENTAL
Intervention: External obturator footprint as a landmark for stem depth
Number of subjects: 135
Study: 33944810

Group type: EXPERIMENTAL
Intervention: Early Physical Therapy after Multiligament Surgery
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (standard care)
Number of subjects: 0
Study: 33944977

Group type: EXPERIMENTAL
Intervention: Cranial microwave scanner in conjunction with nine brain biomarkers (Aβ40, Aβ42, GFAP, H-FABP, S100B, NF-L, NSE, UCH-L1 and IL-10)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Head CT scan
Number of subjects: 0
Study: 33945045

Group type: EXPERIMENTAL
Intervention: Transcranial sonography (TCS)
Number of subjects: 100
Study: 33945049

Group type: EXPERIMENTAL
Intervention: RC48 (2.5 mg/kg Q2W)
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: RC48
Number of subjects: 57
Study: 33945291

Group type: EXPERIMENTAL
Intervention: Chemotherapy with or without focal proton or photon radiation therapy (RT)
Number of subjects: 139
Study: 33945296

Group type: EXPERIMENTAL
Intervention: Pertuzumab plus high-dose trastuzumab (6 mg/kg weekly)
Number of subjects: 39
Study: 33945297

Group type: EXPERIMENTAL
Intervention: Lenvatinib 24 mg once daily until disease progression or treatment intolerance
Number of subjects: 111
Study: 33945304

Group type: EXPERIMENTAL
Intervention: Real-time Continuous Glucose Monitoring (RT-CGM)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Capillary glucose monitoring
Number of subjects: 0
Study: 33945497

Group type: EXPERIMENTAL
Intervention: Wearable sensors (Fitbit Charge 3 smartwatch and TempTraq temperature patches) and smartphone-based symptom logging for 30 days.
Number of subjects: 226

Group type: EXPERIMENTAL
Intervention: Daily mood score logging and symptom reporting via smartphone app (Roadmap 2.0) for 30 days.
Number of subjects: 226

Group type: EXPERIMENTAL
Intervention: Biospecimen collection (nasal swabs, saliva swabs, and blood) for up to 1 year.
Number of subjects: 226
Study: 33945596

Group type: EXPERIMENTAL
Intervention: Contrast-enhanced ultrasound (CEUS) with 2.4 ml SonoVue intravenous bolus
Number of subjects: 2062

Group type: EXPERIMENTAL
Intervention: Contrast-enhanced ultrasound (CEUS)
Number of subjects: 2062
Study: 33945605

Group type: EXPERIMENTAL
Intervention: Whole-blood standard flow cytometric assay to identify pathogenic antibodies associated with VITT
Number of subjects: 0
Study: 33945627

Group type: EXPERIMENTAL
Intervention: Chitosan-based hydrogel supplemented with gelatine and Link N (LN)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Chitosan-based hydrogel with gelatine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Transforming growth factor (TGF)-β (positive control)
Number of subjects: 0
Study: 33946038

Group type: COMPARATOR
Intervention: Critically ill ICU patients
Number of subjects: 51

Group type: COMPARATOR
Intervention: WBP of most AA
Number of subjects: 51

Group type: COMPARATOR
Intervention: Critically ill ICU patients (SOFA 8-16)
Number of subjects: 51

Group type: COMPARATOR
Intervention: WBP of glutamate and glutamine
Number of subjects: 51
Study: 33947116

Group type: EXPERIMENTAL
Intervention: Child-appealing packaging (CAP) coding tool
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Mock breakfast cereal packages
Number of subjects: 15
Study: 33947168

Group type: EXPERIMENTAL
Intervention: HLA-mismatching (A-B-C-DR-DQ)
Number of subjects: 105
Study: 33947205

Group type: EXPERIMENTAL
Intervention: Peripheral Artery Questionnaire (PAQ) summary scale improvement
Number of subjects: 483

Group type: EXPERIMENTAL
Intervention: Peripheral Artery Questionnaire (PAQ) summary scale worsening
Number of subjects: 483
Study: 33947209

Group type: EXPERIMENTAL
Intervention: Alteplase
Number of subjects: 1765

Group type: COMPARATOR
Intervention: Control (no alteplase)
Number of subjects: 1765

Group type: EXPERIMENTAL
Intervention: Overall cohort
Number of subjects: 1765
Study: 33947359

Group type: EXPERIMENTAL
Intervention: Genotyping via saliva samples and bloodspots; comprehensive online phenotyping.
Number of subjects: 14500

Group type: COMPARATOR
Intervention: Controls (1500 individuals)
Number of subjects: 14500
Study: 33947421

Group type: EXPERIMENTAL
Intervention: Liquid meal with moderate protein and carbohydrate content
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Standardized liquid meal
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Two different meals
Number of subjects: 10
Study: 33947443

Group type: EXPERIMENTAL
Intervention: Liquid soap
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Scented soap bar
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Mirror
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control arm (standard hygiene kit)
Number of subjects: 0
Study: 33947471

Group type: EXPERIMENTAL
Intervention: EMDR-only
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: EMDR combined with Dialectical Behaviour Therapy
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Imaginary Rescripting (ImRs)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: ImRs combined with Schema Focused Therapy
Number of subjects: 40

Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 40
Study: 33947696

Group type: EXPERIMENTAL
Intervention: Palbociclib + fixed-dose vemurafenib
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Transcriptomic data
Number of subjects: 18
Study: 33947698

Group type: EXPERIMENTAL
Intervention: KA2507
Number of subjects: 0
Study: 33947745

Group type: EXPERIMENTAL
Intervention: Mediator of DNA Damage Checkpoint 1 (MDC1) as an estrogen receptor coregulator
Number of subjects: 0
Study: 33947785

Group type: EXPERIMENTAL
Intervention: Large mitochondrial DNA (mtDNA) deletions in skin biopsies
Number of subjects: 67
Study: 33948050

Group type: EXPERIMENTAL
Intervention: Filiation service (serve/FP)
Number of subjects: 442

Group type: COMPARATOR
Intervention: Filiation service (did not serve/FN)
Number of subjects: 442

Group type: EXPERIMENTAL
Intervention: FP group
Number of subjects: 442
Study: 33948123

Group type: EXPERIMENTAL
Intervention: Upfront brain radiotherapy (BR) with chemotherapy (platin-pemetrexed and bevacizumab), followed by maintenance pemetrexed with or without bevacizumab.
Number of subjects: 91

Group type: COMPARATOR
Intervention: Chemotherapy (ChT) with brain radiotherapy (BR) only at cerebral progression.
Number of subjects: 91
Study: 33948191

Group type: EXPERIMENTAL
Intervention: Quality improvement intervention
Number of subjects: 10000

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 10000
Study: 33948447

Group type: EXPERIMENTAL
Intervention: ACLR treatment
Number of subjects: 216

Group type: COMPARATOR
Intervention: Non-ACLR treatment
Number of subjects: 216
Study: 33948606

Group type: EXPERIMENTAL
Intervention: DSM-XC (two-factor solution by Lace & Merz, 2020)
Number of subjects: 3533

Group type: EXPERIMENTAL
Intervention: DSM-XC (six-factor solution)
Number of subjects: 3533

Group type: EXPERIMENTAL
Intervention: DSM-XC (bifactor solution)
Number of subjects: 3533
Study: 33948803

Group type: EXPERIMENTAL
Intervention: Physician financial incentive payment of $75 for producing a written post-discharge care plan.
Number of subjects: 409289
Study: 33949004

Group type: EXPERIMENTAL
Intervention: Screw-retained one-piece implant crowns fabricated with zirconia abutments
Number of subjects: 32
Study: 33949080

Group type: EXPERIMENTAL
Intervention: Implant removal due to peri-implantitis with simultaneous bone regeneration procedures and the use of a removal kit
Number of subjects: 26

Group type: COMPARATOR
Intervention: Implant removal due to peri-implantitis
Number of subjects: 26
Study: 33949343

Group type: EXPERIMENTAL
Intervention: Fecobionics device
Number of subjects: 44
Study: 33949944

Group type: EXPERIMENTAL
Intervention: Enhanced ventilatory response to exercise (VE/VCO2 ratio)
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Peak oxygen consumption
Number of subjects: 70
Study: 33949954

Group type: EXPERIMENTAL
Intervention: Counselor feedback duration in the first quarter
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Counselor feedback duration in the second quarter
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Counselor feedback duration in the third quarter
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Counselor feedback duration in the fourth quarter
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Overall feedback duration across 12 months
Number of subjects: 10
Study: 33949959

Group type: EXPERIMENTAL
Intervention: Tailored Internet-delivered cognitive behavioral therapy (ICBT)
Number of subjects: 83
Study: 33949966

Group type: EXPERIMENTAL
Intervention: COVID-19 Decompensation Index (CDI)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Machine learning techniques on a large data set of patients with COVID-19
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Evaluation of the pinpointIQ digital platform
Number of subjects: 0
Study: 33950216

Group type: EXPERIMENTAL
Intervention: Vertical sleeve gastrectomy (VSG)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Preoperative connectivity of PUT.R
Number of subjects: 36
Study: 33950298

Group type: EXPERIMENTAL
Intervention: 18 kDa translocator protein (TSPO) tracers
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Surgical samples
Number of subjects: 0
Study: 33951076

Group type: EXPERIMENTAL
Intervention: Community-based active surveillance
Number of subjects: 350

Group type: EXPERIMENTAL
Intervention: Serostatus determination at enrolment
Number of subjects: 350

Group type: EXPERIMENTAL
Intervention: Testing for suspected dengue cases (RT-qPCR, NS1 assay, IgG and IgM assays)
Number of subjects: 350
Study: 33951232

Group type: COMPARATOR
Intervention: Preataxic mutation carriers
Number of subjects: 321

Group type: COMPARATOR
Intervention: Ataxic mutation carriers
Number of subjects: 321

Group type: EXPERIMENTAL
Intervention: Pontine volume
Number of subjects: 321

Group type: EXPERIMENTAL
Intervention: Multivariate model
Number of subjects: 321
Study: 33951488

Group type: EXPERIMENTAL
Intervention: Hysteroscopic TruClear tissue removal system (Medtronic, Minneapolis, MN)
Number of subjects: 10
Study: 33951732

Group type: EXPERIMENTAL
Intervention: CEBPA-bZip mutations (including CEBPA-double-mutated)
Number of subjects: 2958

Group type: COMPARATOR
Intervention: CEBPA-wild-type (CEBPA-WT)
Number of subjects: 2958

Group type: EXPERIMENTAL
Intervention: CEBPA mutations with co-occurring CSF3R mutations
Number of subjects: 2958

Group type: EXPERIMENTAL
Intervention: CEBPA-mutant or CSF3R-WT
Number of subjects: 2958
Study: 33951890

Group type: EXPERIMENTAL
Intervention: vorinostat/Gem/BuMel
Number of subjects: 501

Group type: EXPERIMENTAL
Intervention: Gem/BuMel
Number of subjects: 501

Group type: EXPERIMENTAL
Intervention: BEAM
Number of subjects: 501

Group type: EXPERIMENTAL
Intervention: BuMel
Number of subjects: 501

Group type: COMPARATOR
Intervention: BEAM (2005-2007)
Number of subjects: 501

Group type: COMPARATOR
Intervention: BEAM (2008-2011)
Number of subjects: 501

Group type: COMPARATOR
Intervention: BEAM (2012-2015)
Number of subjects: 501

Group type: COMPARATOR
Intervention: BEAM (2016-2019)
Number of subjects: 501
Study: 33951923

Group type: EXPERIMENTAL
Intervention: Functional MVD (FFR-significant, functional multivessel disease)
Number of subjects: 610

Group type: EXPERIMENTAL
Intervention: Functional SVD (FFR nonsignificant multivessel disease)
Number of subjects: 610

Group type: EXPERIMENTAL
Intervention: SVD (angiographic single vessel disease)
Number of subjects: 610